High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells

iPSC-derived cardiomyocytes reveal abnormal TGF-β signalling in left ventricular non-compaction cardiomyopathy

(2016) Kazuki Kodo et al.   NATURE CELL BIOLOGY

Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity

(2016) Paul W Burridge et al.   NATURE MEDICINE

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment

(2016) Andrew Hill et al.   BMJ Open

Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy

(2015) Haodi Wu et al.   Cell Stem Cell

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management

(2015) Alfredo Tartarone et al.   Future Oncology

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclic stretch of embryonic cardiomyocytes increases proliferation, growth, and expression while repressing Tgf-β signaling

(2015) Indroneal Banerjee et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies

(2015) Weijuan Li et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Insulin Protects Cardiac Myocytes from Doxorubicin Toxicity by Sp1-Mediated Transactivation of Survivin

(2015) Beom Seob Lee et al.   PLoS One

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

(2015) Orvar Gunnarsson et al.   Cancer Management and Research

Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform

(2014) Arun Sharma et al.   CIRCULATION RESEARCH

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

(2014) G. Kim et al.   CLINICAL CANCER RESEARCH

The Accelerated Approval of Oncologic Drugs

(2014) Vinay Prasad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Chemically defined generation of human cardiomyocytes

(2014) Paul W Burridge et al.   NATURE METHODS

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Multi-parameter In Vitro Screen in Human Stem Cell-Derived Cardiomyocytes Identifies Ponatinib-Induced Structural and Functional Cardiac Toxicity

(2014) Dominique R. Talbert et al.   TOXICOLOGICAL SCIENCES

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

(2013) H. M. Kantarjian et al.   BLOOD

Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells

(2013) Feng Lan et al.   Cell Stem Cell

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

(2013) Ping Liang et al.   CIRCULATION

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct Metabolic Flow Enables Large-Scale Purification of Mouse and Human Pluripotent Stem Cell-Derived Cardiomyocytes

(2012) Shugo Tohyama et al.   Cell Stem Cell

Clinical cardiac safety profile of nilotinib

(2012) T. D. Kim et al.   HAEMATOLOGICA

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

(2012) Jiajie Zang et al.   PLoS One

Stage-Specific Optimization of Activin/Nodal and BMP Signaling Promotes Cardiac Differentiation of Mouse and Human Pluripotent Stem Cell Lines

(2011) Steven J. Kattman et al.   Cell Stem Cell

A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity

(2011) Hui Cheng et al.   CIRCULATION RESEARCH

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome

(2010) Alessandra Moretti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Complications of Cancer Therapy

(2009) Edward T.H. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2009) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY